Monthly Archives: May 2020

What we can learn from the First Peoples of the United States in the era of COVID-19 | TheHill – The Hill

Posted: May 8, 2020 at 10:50 am

News of how COVID-19 has struck the Navajo Nation has begun to penetrate national coverage of the pandemic. The first cases were believed to have spread at a church rally. Now, the coronavirus has overtaken the Nation, causing nearly 2500 cases and over 70 deaths, and continuing to wreak havoc in a region where running water and electricity are luxuries.

But the Navajo are not alone, of course.

Native American communities, often invisible or oversimplified in terms of their health inequities, are the most at risk in the U.S. for severe disease and higher death rates from COVID-19. The factors are complex: A history of higher infection rates from respiratory illness; a higher prevalence of underlying conditions, such as diabetes and heart disease; crowded living conditions that make physical distancing impossible; and for the 2.2 million Native Americans living on rural reservations, access to hospitals which are under resourced is limited. These hospitals serve populations of 15-20,000 in geographies that span the size of Delaware.

The meaning of the novel virus is different for Native Americans. Within their recent history since the arrival of the first European conquistadors, they have experienced waves of decimation from novel viruses, some systematically used by the colonists as germ warfare to wipe out their peoples.

In the late nineteenth and early twentieth centuries, when federal treaties were signed with the Native American peoples in exchange for enormous tracts of lands, Native Americans were promised federally supported free health care and education in perpetuity. In 1955, this responsibility was transferred from the Department of Interior to the newly minted Indian Health Service (IHS). Yet, never did our federal government adequately fund this new health care organization, a breach of trust and respect for the original North Americans.

One only needs to consider that the IHS average per capita spending per user today is $3,333 compared to $12,744 for Medicare and $9,404 for veterans medical spending. The IHS and Tribes have received significant federal funding to respond to the COVID-19 pandemic, but the challenge now is to be able to spend it on what is needed, given the global shortages in supply of health care equipment and personnel.

After a decade of work on infectious diseases with southwestern tribal communities, in 1991 we signed an MOU with Indian Health Service to leverage our joint resources to promote tribal health and health autonomy. During COVID-19, we have seen IHS staff doctors, nurses and community health workers put themselves and their families at personal risk, lacking personal protective equipment (PPE) and other critical needs much like many parts of the world.

In the communities where we have worked, we see the tribal sovereignty of Native peoples affords them a unique capacity to mount their own containment and mitigation strategies. In some places, tribal leaders issued strict ordinances to community members to shelter in place, even before the first cases were confirmed or local states made such declarations, and established unified command systems with IHS partners.

What is happening in Navajo Nation with a rapid surge in COVID-19 cases and a considerable amount of household transmission is what can be expected to happen in other communities heavily impacted by poverty. And the community mitigation strategies that the Navajo developed will have relevance in other settings. For example, in the hardest hit areas on Navajo Nation, local command posts have been established and staffed with strike teams that can deliver essential items food, medication, wood for heating and cooking, hay for livestock so that COVID-19 affected households dont have to send people into the community for these items.

Further, due to the scarcity of available PPE, there has been swift mobilization for local citizens to sew urgently needed masks and gowns. Imagine, once we get to the other side of this public health emergency, these industries may remain and provide new sources of economic development for tribal communities.

The frugal innovations that will come from Indian Country during this pandemic will afford essential lessons for the world and it wont be the first time. Three of the eight vaccines that all U.S. children receive in the first year of life were proven effective with Native American communities. Pedialyte, the standard of care for children to prevent deaths from dehydration during bouts of infectious vomiting or diarrhea, was based on proof of concept with the White Mountain Apache Tribe.

Yet, without additional and sustained resources for Native American health now and in perpetuity, as promised by our federal government, the First Peoples of this continent will continue to suffer the greatest health inequities in the U.S. COVID-19 will be no exception. What Tribal communities achieve in the absence of adequate resources will represent one of the most valiant battles in our countrys war against COVID-19. Together we are stronger.

Allison Barlow, Ph.D, is the director of the Johns Hopkins Center for American Indian Health and senior scientist of International Health at the Johns Hopkins Bloomberg School of Public Health.Laura Hammitt, M.D., is the director of Infectious Disease Programs at the Johns Hopkins Center for American Indian Health and associate professor of International Health at the Johns Hopkins Bloomberg School of Public Health.

Read this article:

What we can learn from the First Peoples of the United States in the era of COVID-19 | TheHill - The Hill

Posted in Germ Warfare | Comments Off

Pandemics In History- 8: Disease As Weapon – ODISHA BYTES – OdishaBytes

Posted: at 10:50 am

Get real time updates directly on you device, subscribe now.

When pandemics have led to persecution of certain communities, which has been pretty common as we discussed in the previous article, they are often accused of using disease as a biological weapon. The Jews were accused of poisoning the wells of the Christians at the time of Black Death for instance. There has been a lot of discussion currently about COVID-19 being used as a biological weapon by China. Although much of these accusations does not hold water, and reflect cultural prejudices, it is also a fact these fears are based on stories about similar use of disease as a biological weapon in history.

As far back as 1000 BC, the Chinese are supposed to have poisoned water sources of their enemies with arsenic. In fact, poisoning or infecting water sources seems to have been a common strategy. The Romans had poisoned the wells of the besieged enemy cities in 130 BC. In the 12th century, the Holy Roman Emperor, Barbarossa is supposed to have used bodies of dead soldiers to poison the wells of enemies. And as recently as in the 1948 Israeli War of Independence, the Red Cross had accused the Israeli militia of releasing the typhoid bacteria into the water supply of the city of Acre, causing an outbreak of typhoid.

The most well-known story of biological warfare in history is linked to the deadliest pandemic in history, the Black Death. It is well established that the plague arrived in Europe at the port of Messina on Genovese trading ships fleeing Kaffa, a Genoese trading port in Crimea. According to many historians, when the Mongol hordes got affected by plague themselves and were on the verge of abandoning their siege of Kaffa, they used catapults to throw diseased corpses inside the city walls. The plague then spread within the city, leading to some Italians fleeing the city on ships carrying the plague with them to Italy and thereby Europe.

Photo:https://militaryhistorynow.com/2014/02/06/we-have-met-the-enemy-and-they-are-small-a-brief-history-of-bug-warfare/

Another well known story of biological warfare is from the wars between the British and the native Indians in America. When the British were besieged by the Delaware Indians at Fort Pitt (which became Pittsburgh) in 1763, they gifted the Indians two blankets and a handkerchief already contaminated with small pox hoping that disease would lead to ending the siege. The attempt has been well documented though the impact has been debatable though the Indians did suffer an outbreak of small pox soon after. Similarly, the small pox epidemic that ravaged the Aborigines in Australia in 1789 has been argued as a case of deliberate infection.

Also Read:Pandemics In History 1: Shipping The Virus

Also Read:Pandemics In History 2: Rats And The PlagueAlso Read:Pandemics In History 3: From Rats To Bats

The development and use of biological weapons in the 20th century is well documented understandably. With the support of scientific advancements, countries started researching and trying out efficient ways of using disease as a biological weapon. By 1933, Japan had built a bioweapons lab in Manchuria, where the notorious Japanese army doctor Shiro Ishii was testing such weapons on Chinese prisoners. Many countries were quick to follow. The US also set up a bioweapon research facility in Maryland. Both the US and the former Soviet Union had developed the technology to spread Yersinia directly and efficiently as an aerosol.

The research and development of biological weapons using disease became so widespread and alarming that most of these countries came together in 1972 to ban them in the Biological and Toxin Weapons Convention. The Soviet Union, however, was believed to be secretly developing biological weapons and that was later confirmed when Dr. Vladimir Pasechnikdefected in 1989 and confirmed the rumours.

Also Read:Pandemics In History 4: A Tale Of Two Countries

Also Read:Pandemics In History 5: India & Pandemics

Also Read:Pandemics In History 6: Pandemonium In Puri

But the weapons that were being developed were targeted unlike the biological weapons in thrillers and science fiction, which targeted the human race including the people developing it. Soon after COVID-19 broke out, excerpts from the novel Eyes of Darkness by Dean Koontz became viral and it was hailed as a prophetic novel for talking about Wuhan-400, the germ developed at the lab outside Wuhan, and which can wipe out entire cities and countries. What many do not know is that this novel was first published in 1981 at the height of the Cold War, and the germ was called Gorky-400 in the first edition. When the 2nd edition was published in 1989 at the end of the Cold War, it was renamed as Wuhan-400 as China was the new threat to the US.

Photo: https://www.siasat.com/wuhan-400-novel-predicted-coronavirus-40-years-ago-1830971/

It is because of this recent history of the development of biological weaponry, which was highly targeted and designed to ensure minimal fatalities on the sides of the attackers that many experts of biological weapons such as Dan Kaszeta argue quite convincingly that COVID-19 is not a biological weapon.

Also Read: Pandemics In History 7: Pandemics And Persecution

The rest is here:

Pandemics In History- 8: Disease As Weapon - ODISHA BYTES - OdishaBytes

Posted in Germ Warfare | Comments Off

What Are The Best Penny Stocks To Watch This Week? 3 For Your List – Penny Stocks

Posted: at 10:50 am

Are These On Your List Of Penny Stocks To Watch In May 2020?

Regardless of which names are on your list of penny stocks, this week will be an interesting one. While the coronavirus captivated headlines most of this year, China trade could be a focus for the broader markets.

Last week, President Trump threatened to reignite a China trade war in the middle of a global recession and pandemic. This ended up sending the major indexes sharply lower on Friday. Over the weekend this has continued to gain buzz online. Over the weekend, we also saw comments from the Oracle of Omaha, Warren Buffett. He told shareholders at the annual Berkshire meeting that the firm sold its holdings in airline stocks amid the coronavirus pandemic.

[Special Report]The Biggest Market Opportunity Of 2020: Coronavirus

I think there are certain industries, and unfortunately, I think that the airline industry, among others, that are really hurt by a forced shutdown by events that are far beyond our control, he said. Theres no doubt that investors have taken into account the lasting effects of the novel coronavirus pandemic. Will airline stocks recover? Thats a question better suited for when the economy is back to some kind of normal in my opinion.

What has also gained attention over the weekend were comments made by Gilead (GILD Stock Report). The companys CEO, Daniel ODay told CBS Face of the Nation that the company intends to get remdesivir to patients in the early part of this coming week. Gileads CEO said it wants to work with the government to determine which cities are most vulnerable and where the patients are that need this medicine.

In addition to this Gilead also donated its entire supply of the drug to the U.S. Government. Whether thats good or bad, it has shown the company aims to find a solution for this virus. ODay said, Weve donated the entire supply that we have within our supply chain and we did that because we acknowledge and recognize the human suffering, the human need here, and want to make sure nothing gets in the way of this getting to patients.

Last week the company released preliminary results from a clinical trial. It showed 50% of the COVID-19 patients that were treated saw improvement with a 5-day dose. The company expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of the month. It also expects to make around 1 million rounds by the end of 2020. Needless to say, there is still much more attention on companies working to address side-effects of the virus and will likely be a focus during the week ahead.

Penny Stock Basics: What Is The Best App For Penny Stocks?

Last week Algernon Pharmaceuticals (AGNPF Stock Report) (AGN) revealed big news last week on its latest treatment progress. Algernon announced late Wednesday afternoon that it has received a No Objection Letter from Health Canada to proceed with a NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory authorities.

The trial will begin as a Phase 2b study and after an interim analysis is performed on the first 100 patients, the data will determine the number of expected patients needed to reach statistical significance in a Phase 3 trial. With positive preliminary data, the clinical trial will move directly from a Phase 2b into a Phase 3.

This news came on the heels of Algernons receipt of regulatory and ethics approval for Phase 2 Ifenprodil COVID-19 human study in South Korea. The company has even received positive feedback from the U.S. FDA for a new intravenous formulation of the treatment. The FDA has advised that for the toxicology program of the new intravenous Ifenprodil formulation, a single animal 30-day study would be acceptable.

With all of this progress, Algernon stock has managed to reach new all-time highs of $0.4867 and marked a run of 188% from April 1 to April 30th. After the late-week pullback from highs, is Algernon set for another rally in May?

One of the late-breaking penny stocks to watch from last week was Fluidigm Corporation (FLDM Stock Report). For most of the Friday session, shares of FLDM stock were quiet. But during the later afternoon session, the penny stock shot up from around $2.15 to highs of $4.39. Why did Fluidigm stock rally so strongly last week?

To get a better understanding, you should know what the company does. Fluidigm focuses on cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company has a multi-omic solution for testing and diagnostics. Fluidigm began focusing its efforts on COVID-19 to research applications for SARS-CoV-2 virus detection. To this end, FLDM stock managed to take off after the company gained attention in an article on The Guardians website.

Titled US germ warfare research leads to new early Covid-19 test, the article discusses a test that has the potential to identify carriers before they become infectious. Within the article released on May 1, Chris Linthwaite, the chief executive of Fluidigm was quoted. He said that this test could have exceptional demand. Hes referring to a project involving Fluidigm to develop a blood-based test. The goal is to be able to detect a viruss presence as early as 24 hours after infection.

According to the Guardian, the test has emerged from a project set up by the US militarys Defense Advanced Research Projects Agency (Darpa). Its aimed at rapid diagnosis of germ or chemical warfare poisoning. It was hurriedly repurposed when the pandemic broke out according to The Guardian. The new test is expected to be put forward for emergency use approval by the US FDA within a week.

Shares of Millendo Therapeutics Inc. (MLND Stock Report) saw a strong close to the week last week. The penny stock tumbled in early April after reporting unsuccessful results from a Phase 2b clinical trial. The trial was for evaluating lead drug livoletide in patients with Prader-Willi syndrome. Its an inherited disorder characterized by obesity and type 2 diabetes due to insatiable hunger.

After dropping to lows of $1.26, MLND stock has been working to regain its previous trading levels. There is still a long way to go considering that earlier this year, MLND traded above $9 a share. Needless to say, hopes remain high for some of the perma-longs in this stock. Friday saw MLND stock kick May off with a bang. More than 6.4 million shares traded while the penny stock reached a high of $2.13. After closing at $1.85, the buzz surrounds what comes next.

Millendo hasnt released any big updates to speak of. Furthermore, the last corporate filing simply included the companys filed proxy statement on April 24. However, something of note came in a statement made during the April 6 result PR that could have sparked interest in the company.

With the rapidly evolving COVID-19 global pandemic and the extraordinary burden it has put on hospitals and healthcare providers, we are monitoring the potential impact of the situation on these programs and will provide an update when we have more clarity on expected timelines.

Click for full disclaimer

Midam Ventures, LLC | (305) 306-3854 | 1501 Venera Ave, Coral Gables, FL 33146 | news@pennystocks.com

Read this article:

What Are The Best Penny Stocks To Watch This Week? 3 For Your List - Penny Stocks

Posted in Germ Warfare | Comments Off

Time to heed the warning bell – The Japan Times

Posted: at 10:49 am

These are my thought about the recent coronavirus pandemic.

Human beings have been dominating all other species on Earth. Now, the human is the only dictator, controlling other creatures, harvesting plants, feeding livestock, catching fish, consuming fossil fuels, producing various merchandise, polluting the air, contaminating oceans, extinguishing forests, melting icebergs, warming climates and exploding our population. All these elements have been accumulating. Human longevity has improved, so many people are concentrating in big cities and can transport over borders. Is this a real evolution? Is this the right direction for our future? Since this pandemic spread, it is really ironic that the environment has been gradually getting better. This is because we came to a point where we had to stop or slow down our basic, productive and social activities to prevent the virus from spreading. I suppose these circumstances seem comfortable and convenient for other species. Mother Earth would be blessed with the absence of humans. What I mean here is the present crisis is supposed to be a kind of punishment from God to conceited humans. Humans got too arrogant, did too much. We should recognize what we have damaged, sacrificed. The pursuit of our comfort and material wealth may not be the only way to sustain our society. We should stop now and think about better and more different ways to coexist with other creatures and Mother Earth.

Now is the moment when the warning bell is ringing loudly.

We have to listen to this sound carefully for assessing our past sins and reforming for the future.

However, like repeating history, we will perhaps again overcome this crisis with our shrewd intelligence and gigantic power without reflecting on ourselves. Furthermore, fortunately, or unfortunately, we are getting back to the previous normal and going in the same direction as ever.

I just hope we "don't miss the bell."

Aizumisato, Fukushima Prefecture

The opinions expressed in this letter to the editor are the writers own and do not necessarily reflect the policies of The Japan Times.

Originally posted here:
Time to heed the warning bell - The Japan Times

Posted in Human Longevity | Comments Off

Adrenomyeloneuropathy Treatment Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026|…

Posted: at 10:49 am

Latest Report On Adrenomyeloneuropathy Treatment Market including Market Landscape, and Market size, Revenues by players, Revenues by regions, Average prices, Competitive landscape, market Dynamics and industry trends and developments during the forecast period.

The global Adrenomyeloneuropathy Treatment market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Adrenomyeloneuropathy Treatment market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global market. The authors of the report profile leading companies of the global Adrenomyeloneuropathy Treatment market, Also the details about important activities of leading players in the competitive landscape.

Key companies operating in the global Adrenomyeloneuropathy Treatment market include: :, Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1664172/global-adrenomyeloneuropathy-treatment-market

The report predicts the size of the global Adrenomyeloneuropathy Treatment market in terms of value and volume for the forecast period 2020-2026. As per the analysis provided in the report, the global Adrenomyeloneuropathy Treatment market is expected to rise at a CAGR of xx % between 2020 and 2026 to reach a valuation of US$ xx million/billion by the end of 2026. In 2020, the global Adrenomyeloneuropathy Treatment market attained a valuation of US$ XX million/billion. The market researchers deeply analyze the global Adrenomyeloneuropathy Treatment industry landscape and the future prospects it is anticipated to create

Segmental Analysis

The report has classified the global Adrenomyeloneuropathy Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Adrenomyeloneuropathy Treatment manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Adrenomyeloneuropathy Treatment industry.

Global Adrenomyeloneuropathy Treatment Market Segment By Type:

, Steroid Replacement Therapy, Stem Cell Transplant By the end users,

Global Adrenomyeloneuropathy Treatment Market Segment By Application:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Adrenomyeloneuropathy Treatment market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Adrenomyeloneuropathy Treatment industry. Based on our recent survey, we have several different scenarios about the Adrenomyeloneuropathy Treatment YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Adrenomyeloneuropathy Treatment will reach xx in 2026, with a CAGR of xx% from 2020 to 2026. Global Adrenomyeloneuropathy Treatment market: Drivers and Restraints This section covers the various factors driving the global Adrenomyeloneuropathy Treatment market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market. Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market. Global Adrenomyeloneuropathy Treatment market: Segment Analysis The global Adrenomyeloneuropathy Treatment market is split into two segments, type, and application. The product type briefs on the various types of products available in the market. The report also provides data for each product type by revenue for the forecast time period. It covers the price of each type of product. The other segment on the report, application, explains the various uses of the product and end-users. In the report, the researchers have also provided revenue according to the consumption of the product. Global Adrenomyeloneuropathy Treatment market: Regional Analysis The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026. Global Adrenomyeloneuropathy Treatment market: Key Players The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market. By the therapy, the market is primarily split into, Steroid Replacement Therapy, Stem Cell Transplant By the end users, Hospitals, Clinics, Ambulatory Surgical Centers, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Adrenomyeloneuropathy Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key questions answered in the report:

Enquire for Customization in the report @ https://www.qyresearch.com/customize-request/form/1664172/global-adrenomyeloneuropathy-treatment-market

TOC

1 Market Overview of Adrenomyeloneuropathy Treatment1.1 Adrenomyeloneuropathy Treatment Market Overview1.1.1 Adrenomyeloneuropathy Treatment Product Scope1.1.2 Market Status and Outlook1.2 Global Adrenomyeloneuropathy Treatment Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Adrenomyeloneuropathy Treatment Market Size by Region (2015-2026)1.4 Global Adrenomyeloneuropathy Treatment Historic Market Size by Region (2015-2020)1.5 Global Adrenomyeloneuropathy Treatment Market Size Forecast by Region (2021-2026)1.6 Key Regions Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.1 North America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.2 Europe Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.3 China Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.5 Latin America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Adrenomyeloneuropathy Treatment Industry Impact1.7.1 How the Covid-19 is Affecting the Adrenomyeloneuropathy Treatment Industry

1.7.1.1 Adrenomyeloneuropathy Treatment Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Adrenomyeloneuropathy Treatment Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Adrenomyeloneuropathy Treatment Players to Combat Covid-19 Impact 2 Adrenomyeloneuropathy Treatment Market Overview by Therapy2.1 Global Adrenomyeloneuropathy Treatment Market Size by Therapy: 2015 VS 2020 VS 20262.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by Therapy (2015-2020)2.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Therapy (2021-2026)2.4 Steroid Replacement Therapy2.5 Stem Cell Transplant 3 Adrenomyeloneuropathy Treatment Market Overview by Therapy3.1 Global Adrenomyeloneuropathy Treatment Market Size by End Users: 2015 VS 2020 VS 20263.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by End Users (2015-2020)3.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by End Users (2021-2026)3.4 Hospitals3.5 Clinics3.6 Ambulatory Surgical Centers3.7 Others 4 Global Adrenomyeloneuropathy Treatment Competition Analysis by Players4.1 Global Adrenomyeloneuropathy Treatment Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenomyeloneuropathy Treatment as of 2019)4.3 Date of Key Manufacturers Enter into Adrenomyeloneuropathy Treatment Market4.4 Global Top Players Adrenomyeloneuropathy Treatment Headquarters and Area Served4.5 Key Players Adrenomyeloneuropathy Treatment Product Solution and Service4.6 Competitive Status4.6.1 Adrenomyeloneuropathy Treatment Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Ascend Biopharmaceuticals5.1.1 Ascend Biopharmaceuticals Profile5.1.2 Ascend Biopharmaceuticals Main Business and Companys Total Revenue5.1.3 Ascend Biopharmaceuticals Products, Services and Solutions5.1.4 Ascend Biopharmaceuticals Revenue (US$ Million) (2015-2020)5.1.5 Ascend Biopharmaceuticals Recent Developments5.2 Novadip Biosciences5.2.1 Novadip Biosciences Profile5.2.2 Novadip Biosciences Main Business and Companys Total Revenue5.2.3 Novadip Biosciences Products, Services and Solutions5.2.4 Novadip Biosciences Revenue (US$ Million) (2015-2020)5.2.5 Novadip Biosciences Recent Developments5.3 Eureka Therapeutics5.5.1 Eureka Therapeutics Profile5.3.2 Eureka Therapeutics Main Business and Companys Total Revenue5.3.3 Eureka Therapeutics Products, Services and Solutions5.3.4 Eureka Therapeutics Revenue (US$ Million) (2015-2020)5.3.5 Human Longevity Recent Developments5.4 Human Longevity5.4.1 Human Longevity Profile5.4.2 Human Longevity Main Business and Companys Total Revenue5.4.3 Human Longevity Products, Services and Solutions5.4.4 Human Longevity Revenue (US$ Million) (2015-2020)5.4.5 Human Longevity Recent Developments5.5 Regeneus5.5.1 Regeneus Profile5.5.2 Regeneus Main Business and Companys Total Revenue5.5.3 Regeneus Products, Services and Solutions5.5.4 Regeneus Revenue (US$ Million) (2015-2020)5.5.5 Regeneus Recent Developments5.6 Allogene Therapeutics5.6.1 Allogene Therapeutics Profile5.6.2 Allogene Therapeutics Main Business and Companys Total Revenue5.6.3 Allogene Therapeutics Products, Services and Solutions5.6.4 Allogene Therapeutics Revenue (US$ Million) (2015-2020)5.6.5 Allogene Therapeutics Recent Developments5.7 BioRestorative Therapies5.7.1 BioRestorative Therapies Profile5.7.2 BioRestorative Therapies Main Business and Companys Total Revenue5.7.3 BioRestorative Therapies Products, Services and Solutions5.7.4 BioRestorative Therapies Revenue (US$ Million) (2015-2020)5.7.5 BioRestorative Therapies Recent Developments5.8 Immatics Biotechnologies5.8.1 Immatics Biotechnologies Profile5.8.2 Immatics Biotechnologies Main Business and Companys Total Revenue5.8.3 Immatics Biotechnologies Products, Services and Solutions5.8.4 Immatics Biotechnologies Revenue (US$ Million) (2015-2020)5.8.5 Immatics Biotechnologies Recent Developments5.9 NewLink Genetics5.9.1 NewLink Genetics Profile5.9.2 NewLink Genetics Main Business and Companys Total Revenue5.9.3 NewLink Genetics Products, Services and Solutions5.9.4 NewLink Genetics Revenue (US$ Million) (2015-2020)5.9.5 NewLink Genetics Recent Developments5.10 Cytori Therapeutics5.10.1 Cytori Therapeutics Profile5.10.2 Cytori Therapeutics Main Business and Companys Total Revenue5.10.3 Cytori Therapeutics Products, Services and Solutions5.10.4 Cytori Therapeutics Revenue (US$ Million) (2015-2020)5.10.5 Cytori Therapeutics Recent Developments5.11 Talaris Therapeutics5.11.1 Talaris Therapeutics Profile5.11.2 Talaris Therapeutics Main Business and Companys Total Revenue5.11.3 Talaris Therapeutics Products, Services and Solutions5.11.4 Talaris Therapeutics Revenue (US$ Million) (2015-2020)5.11.5 Talaris Therapeutics Recent Developments 6 North America Adrenomyeloneuropathy Treatment by Players and by End Users6.1 North America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)6.2 North America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 7 Europe Adrenomyeloneuropathy Treatment by Players and by End Users7.1 Europe Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)7.2 Europe Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 8 China Adrenomyeloneuropathy Treatment by Players and by End Users8.1 China Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)8.2 China Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 9 Rest of Asia Pacific Adrenomyeloneuropathy Treatment by Players and by End Users9.1 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 10 Latin America Adrenomyeloneuropathy Treatment by Players and by End Users10.1 Latin America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)10.2 Latin America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 11 Middle East & Africa Adrenomyeloneuropathy Treatment by Players and by End Users11.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 12 Adrenomyeloneuropathy Treatment Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Continued here:
Adrenomyeloneuropathy Treatment Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026|...

Posted in Human Longevity | Comments Off

Precision Medicine Software Market to See Massive Growth by 2026| Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation…

Posted: at 10:49 am

Global Precision Medicine Software Market: Trends Estimates High Demand by 2027

The Precision Medicine Software Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Precision Medicine Software Industry Report is an in-depth study analyzing the current state of the Precision Medicine Software Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Precision Medicine Software Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Precision Medicine Software market. All findings and data on the global Precision Medicine Software market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Precision Medicine Software market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Precision Medicine Software industry.

Some of the companies competing in the Precision Medicine Software markets are: Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation Medicine, Sophia Genetics, PierianDx, Human Longevity, Translational Software, Gene42, Inc, Lifeomic Health

Get a Free Sample [emailprotected] https://www.reportsandmarkets.com/sample-request/global-precision-medicine-software-market-2019-by-company-regions-type-and-application-forecast-to-2024

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Precision Medicine Software Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Precision Medicine Software Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Precision Medicine Software market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Precision Medicine Software market report answer pertaining to the regional reach of the industry

The report claims to split the regional scope of the Precision Medicine Software market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present How does the sales scenario look for the future

Considering the present scenario, how much revenue will each region attain by the end of the forecast period

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Precision Medicine Software market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Precision Medicine Software Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Precision Medicine Software Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Precision Medicine Software Market Effect Factors Analysis

Chapter 12: GlobalPrecision Medicine Software Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/global-precision-medicine-software-market-2019-by-company-regions-type-and-application-forecast-to-2024

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read the original here:
Precision Medicine Software Market to See Massive Growth by 2026| Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation...

Posted in Human Longevity | Comments Off

Millions of historic newspaper images get the machine learning treatment at the Library of Congress – TechCrunch

Posted: at 10:48 am

Historians interested in the way events and people were chronicled in the old days once had to sort through card catalogs for old papers, then microfiche scans, then digital listings but modern advances can index them down to each individual word and photo. A new effort from the Library of Congress has digitized and organized photos and illustrations from centuries of news using state of the art machine learning.

Led by Ben Lee, a researcher from the University of Washington occupying the Librarys Innovator in Residence position, the Newspaper Navigator collects and surfaces data from images from some 16 million pages of newspapers throughout American history.

Lee and his colleagues were inspired by work already being done in Chronicling America, an ongoing digitization effort for old newspapers and other such print materials. While that work used optical character recognition to scan the contents of all the papers, there was also a crowdsourced project in which people identified and outlined images for further analysis. Volunteers drew boxes around images relating to World War I, then transcribed the captions and categorized the picture.

This limited effort set the team thinking.

I loved it because it emphasized the visual nature of the pages seeing the visual diversity of the content coming out of the project, I just thought it was so cool, and I wondered what it would be like to chronicle content like this from all over America, Lee told TechCrunch.

He also realized that what the volunteers had created was in fact an ideal set of training data for a machine learning system. The question was, could we use this stuff to create an object detection model to go through every newspaper, to throw open the treasure chest?

The answer, happily, was yes. Using the initial human-powered work of outlining images and captions as training data, they built an AI agent that could do so on its own. After the usual tweaking and optimizing, they set it loose on the full Chronicling America database of newspaper scans.

It ran for 19 days nonstop definitely the largest computing job Ive ever run, said Lee. But the results are remarkable: millions of images spanning three centuries (from 1789 to 1963) and organized with metadata pulled from their own captions. The team describes their work in a paper you can read here.

Assuming the captions are at all accurate, these images until recently only accessible by trudging through the archives date by date and document by document can be searched for by their contents, like any other corpus.

Looking for pictures of the president in 1870? No need to browse dozens of papers looking for potential hits and double-checking the contents in the caption just search Newspaper Navigator for president 1870. Or if you want editorial cartoons from the World War II era, you can just get all illustrations from a date range. (The team has already zipped up the photos into yearly packages and plans other collections.)

Here are a few examples of newspaper pages with the machine learning systems determinations overlaid on them (warning: plenty of hat ads and racism):

Thats fun for a few minutes for casual browsers, but the key thing is what it opens up for researchers and other sets of documents. The team is throwing a data jam today to celebrate the release of the data set and tools, during which they hope to both discover and enable new applications.

Hopefully it will be a great way to get people together to think of creative ways the data set can be used, said Lee. The idea Im really excited by from a machine learning perspective is trying to build out a user interface where people can build their own data set. Political cartoons or fashion ads, just let users define theyre interested in and train a classifier based on that.

A sample of what you might get if you asked for maps from the Civil War era.

In other words, Newspaper Navigators AI agent could be the parent for a whole brood of more specific ones that could be used to scan and digitize other collections. Thats actually the plan within the Library of Congress, where the digital collections team has been delighted by the possibilities brought up by Newspaper Navigator, and machine learning in general.

One of the things were interested in is how computation can expand the way were enabling search and discovery, said Kate Zwaard. Because we have OCR, you can find things it would have taken months or weeks to find. The Librarys book collection has all these beautiful plates and illustrations. But if you want to know like, what pictures are there of the Madonna and child, some are categorized, but others are inside books that arent catalogued.

That could change in a hurry with an image-and-caption AI systematically poring over them.

Newspaper Navigator, the code behind it and all the images and results from it are completely public domain, free to use or modify for any purpose. You can dive into the code at the projects GitHub.

See the article here:

Millions of historic newspaper images get the machine learning treatment at the Library of Congress - TechCrunch

Comments Off

Could quantum machine learning hold the key to treating COVID-19? – Tech Wire Asia

Posted: at 10:48 am

Sundar Pichai, CEO of Alphabet with one of Googles quantum computers. Source: AFP PHOTO / GOOGLE/HANDOUT

Scientific researchers are hard at work around the planet, feverishly crunching data using the worlds most powerful supercomputers in the hopes of a speedier breakthrough in finding a vaccine for the novel coronavirus.

Researchers at Penn State University think that they have hit upon a solution that could greatly accelerate the process of discovering a COVID-19 treatment, employing an innovative hybrid branch of research known as quantum machine learning.

When it comes to a computer science-driven approach to identifying a cure, most methodologies harness machine learning to screen different compounds one at a time to see if they might bond with the virus main protease, or protein.

This process is arduous and time-consuming, despite the fact that the most powerful computers were actually condensing years (maybe decades) of drug testing into less than two years time. Discovering any new drug that can cure a disease is like finding a needle in a haystack, said lead researcher Swaroop Ghosh, the Joseph R. and Janice M. Monkowski Career Development Assistant Professor of Electrical Engineering and Computer Science and Engineering at Penn State.

It is also incredibly expensive. Ghosh says the current pipeline for discovering new drugs can take between five and ten years from the concept stage to being released to the market, and could cost billions in the process.

High-performance computing such as supercomputers and artificial intelligence (AI) canhelp accelerate this process by screeningbillions of chemical compounds quicklyto findrelevant drugcandidates, he elaborated.

This approach works when enough chemical compounds are available in the pipeline, but unfortunately this is not true for COVID-19. This project will explorequantum machine learning to unlock new capabilities in drug discovery by generating complex compounds quickly.

Quantum machine learning is an emerging field that combines elements of machine learning with quantum physics. Ghosh and his doctoral students had in the past developed a toolset for solving a specific set of problems known as combinatorial optimization problems, using quantum computing.

Drug discovery computation aligns with combinatorial optimization problems, allowing the researchers to tap the same toolset in the hopes of speeding up the process of discovering a cure, in a more cost-effective fashion.

Artificial intelligence for drug discovery is a very new area, Ghosh said. The biggest challenge is finding an unknown solution to the problem by using technologies that are still evolving that is, quantum computing and quantum machine learning. We are excited about the prospects of quantum computing in addressing a current critical issue and contributing our bit in resolving this grave challenge.

Joe Devanesan | @thecrystalcrown

Joe's interest in tech began when, as a child, he first saw footage of the Apollo space missions. He still holds out hope to either see the first man on the moon, or Jetsons-style flying cars in his lifetime.

Continued here:

Could quantum machine learning hold the key to treating COVID-19? - Tech Wire Asia

Comments Off

Udacity partners with AWS to offer scholarships on machine learning for working professionals – Business Insider India

Posted: at 10:48 am

All applicants will be able to join the AWS Machine Learning Foundations Course. While applications are on currently, enrollment for the course begins on May 19.

This course will provide an understanding of software engineering and AWS machine learning concepts including production-level coding and practice object-oriented programming. They will also learn about deep learning techniques and its applications using AWS DeepComposer. Advertisement

A major reason behind the increasing uptake of such niche courses among the modern-age learners has to do with the growing relevance of technology across all spheres the world over. In its wake, many high-value job roles are coming up that require a person to possess immense technical proficiency and knowledge in order to assume them. And machine learning is one of the key components of the ongoing AI revolution driving digital transformation worldwide, said Gabriel Dalporto, CEO of Udacity.

The top 325 performers in the foundation course will be awarded with a scholarship to join Udacitys Machine Learning Engineer Nanodegree program. In this advanced course, the students will work on ML tools from AWS. This includes real-time projects that are focussed on specific machine learning skills.

The Nanodegree program scholarship will begin on August 19.

Webinar: Transform Data into Actionable Intelligence: How to Reach Operational Excellence with Machine Learning – World Cement

Posted: at 10:48 am

Unlocking the power of Artificial Intelligence and Machine Learning (AI/ML) is projected to drive the next generation of industrial manufacturing.

Actionable intelligence is not created equal, as there is a clear difference in performance between organisations using simple analytics and modeling tools, and those who embrace predictive and prescriptive insights into their decision-making processes and company culture.

With initiatives to increase yield, improve energy recovery, and stabilise operations, cement producers are facing how to best leverage technology and their existing data to drive measurable business results.

Petuums award-winning AI/ML products bring capabilities above and beyond traditional process control techniques. Petuum takes a data-driven and dynamic approach to improve process workflows, with the ability to configure AI models based on your operating preferences and ever-changing business goals and constraints.

During this webinar, Petuum will present:

CEMEX, one of Petumms global customers, says, Petuum helped us achieve something we didnt think was possible. We expect our yield improvements and energy savings to be up to 7%.

View post:

Webinar: Transform Data into Actionable Intelligence: How to Reach Operational Excellence with Machine Learning - World Cement

Comments Off

Monthly Archives: May 2020

What we can learn from the First Peoples of the United States in the era of COVID-19 | TheHill – The Hill

Pandemics In History- 8: Disease As Weapon – ODISHA BYTES – OdishaBytes

What Are The Best Penny Stocks To Watch This Week? 3 For Your List – Penny Stocks

Time to heed the warning bell – The Japan Times

Adrenomyeloneuropathy Treatment Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026|…

Precision Medicine Software Market to See Massive Growth by 2026| Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation…

Millions of historic newspaper images get the machine learning treatment at the Library of Congress – TechCrunch

Could quantum machine learning hold the key to treating COVID-19? – Tech Wire Asia

Udacity partners with AWS to offer scholarships on machine learning for working professionals – Business Insider India

Webinar: Transform Data into Actionable Intelligence: How to Reach Operational Excellence with Machine Learning – World Cement

The Prometheus League

Breaking News and Updates

Prometheism

Forbidden Fruit

The Evolutionary Perspective

Transtopia Menu

Library Updates

Library Books

Future Euvolution

Lucid Dreams from Childhood

Genetic Revolution

Speciation + Self-Directed Evolution